Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason P. Rhodes Sells 782 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason P. Rhodes sold 782 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the transaction, the director now owns 15,962 shares of the company’s stock, valued at $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $29.34 on Tuesday. The firm’s 50 day simple moving average is $32.42 and its 200-day simple moving average is $35.26. Dyne Therapeutics, Inc. has a 12 month low of $10.03 and a 12 month high of $47.45. The stock has a market capitalization of $2.99 billion, a price-to-earnings ratio of -8.24 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Analysts anticipate that Dyne Therapeutics, Inc. will post -3.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC raised its position in Dyne Therapeutics by 4.3% during the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after acquiring an additional 352 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares during the last quarter. KBC Group NV lifted its stake in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after buying an additional 796 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DYN shares. Oppenheimer reissued an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Piper Sandler restated an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Stifel Nicolaus lifted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Morgan Stanley upped their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.